Docetaxel trials for Pancreatic cancer

All Docetaxel trials · All Pancreatic cancer trials

Phase breakdown

Recruiting trials studying Docetaxel for Pancreatic cancer

• A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
  NCT04895709 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 94 locations
• Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)
  NCT05431270 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 6 locations
• MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors
  NCT05076760 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Safety of Combining Irinotecan With 5-FU, Leucovorin/Folinic Acid, Oxaliplatin, and Docetaxel Chemotherapies
  NCT04361708 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location

Common questions

How many trials study Docetaxel for Pancreatic cancer?

4 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.